On November 5, 2024 PharmaMar Group (MSE: PHM) has received a $10 million payment from Janssen Products LP (Janssen), a subsidiary of Johnson & Johnson, upon reaching a commercial milestone established in the licensing agreement for Yondelis (trabectedin) in the United States (Press release, PharmaMar, NOV 5, 2024, View Source [SID1234647674]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In August 2019, PharmaMar signed a new licensing agreement with Johnson & Johnson that replaced the 2001 agreement under which Johnson & Johnson reserved the right to exclusively sell and distribute trabectedin in the United States.

Currently, trabectedin is approved in more than 70 countries for the treatment of soft tissue sarcoma and also in some of these countries for ovarian cancer.